Issue Date: December 21, 2015
AstraZeneca Snags Stake In Acerta …
AstraZeneca has agreed to pay $4 billion for a 55% stake in privately held Acerta Pharma. The centerpiece of the deal is acalabrutinib, a second-generation BTK inhibitor in Phase III studies to treat certain blood cancers. If successful, the molecule would compete with Imbruvica, an approved BTK inhibitor developed by Pharmacyclics, which AbbVie acquired earlier this year for $21 billion. AstraZeneca has also secured an option to acquire the remaining shares in Acerta for roughly $3 billion.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society